PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.42%
Revenue growth of 10.42% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
8.17%
Gross profit growth of 8.17% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-1.82%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
18.93%
Operating income growth of 18.93% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
1.60%
Net income growth of 1.60% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
1.65%
EPS growth of 1.65% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
1.65%
Diluted EPS growth of 1.65% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
99.82%
Dividend growth of 99.82% while Medical - Pharmaceuticals median is flat. Walter Schloss might appreciate at least a modest improvement.
-52.95%
Negative OCF growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-67.96%
Negative FCF growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
15.33%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 7.03%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
15.33%
5Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 12.19%. Mohnish Pabrai might attribute the outperformance to scale or brand strength.
15.33%
3Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 13.16%. Mohnish Pabrai would attribute it to strong near-term market positioning.
129.00%
OCF/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 34.47% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
129.00%
5Y OCF/share growth exceeding 1.5x Medical - Pharmaceuticals median of 39.08%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
129.00%
3Y OCF/share growth > 1.5x Medical - Pharmaceuticals median of 16.74%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
8.12%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper issues limiting long-term profit growth.
8.12%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
8.12%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos might see a red flag indicating fundamental short-term issues in profitability or cost control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.20%
Dividend/share CAGR of 53.20% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
53.20%
5Y dividend/share CAGR of 53.20% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
53.20%
3Y dividend/share CAGR of 53.20% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
No Data
No Data available this quarter, please select a different quarter.
-4.73%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
2.98%
Asset growth of 2.98% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.13%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
-24.33%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.